Susquehanna International Group’s CG Oncology CGON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.04M Buy
+30,200
New +$1.71M ﹤0.01% 6133
2025
Q4
Sell
-9,000
Closed -$363K 12456
2025
Q3
$363K Sell
9,000
-151,800
-94% -$4.41M ﹤0.01% 9687
2025
Q2
$4.18M Buy
+160,800
New +$3.87M ﹤0.01% 4314
2024
Q4
Sell
-30,300
Closed -$1.14M 12277
2024
Q3
$1.14M Buy
30,300
+23,900
+373% +$838K ﹤0.01% 6478
2024
Q2
$202K Buy
+6,400
New +$222K ﹤0.01% 10340

Other funds holding CGON

Susquehanna International Group's CGON Position: Q1 2026 in Review

Susquehanna International Group opened a new position in CG Oncology (CGON) in Q1 2026: 25,803 shares worth $1.75M. The stake represents ﹤0.01% of the portfolio and ranks #6488 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CGON as recently as Q2 2025.

Susquehanna International Group first reported a position in CGON in Q1 2024 and has held it in 6 quarters since. The position peaked at $2.44M in Q2 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Susquehanna International Group held 25,803 shares of CG Oncology worth $1.75M as of Q1 2026.
  • CG Oncology was a new Susquehanna International Group position in Q1 2026.
  • CG Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6488 holding.
  • Susquehanna International Group first reported a position in CG Oncology in Q1 2024 and has held it in 6 quarters since.
  • Susquehanna International Group's CG Oncology position peaked at $2.44M in Q2 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.